XTSXQPT
Market cap22mUSD
Oct 20, Last price
0.08CAD
Name
Quest Pharmatech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-58.30%
Revenues
0k
Net income
-3m
L-95.35%
CFO
-342k
L-38.27%
Earnings
Jun 26, 2025
Profile
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 1,316 | 834 | 791 | ||
Unusual Expense (Income) | |||||
NOPBT | (1,316) | (834) | (791) | ||
NOPBT Margin | |||||
Operating Taxes | (2,625) | (57,500) | |||
Tax Rate | |||||
NOPAT | (1,316) | 1,791 | 56,709 | ||
Net income | (3,018) -95.35% | (64,888) -23.70% | (85,039) -144.74% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 90 | ||||
BB yield | |||||
| Debt | |||||
Debt current | 1,000 | 1,000 | 514 | ||
Long-term debt | 14 | ||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (23,351) | (25,542) | (90,450) | ||
| Cash flow | |||||
Cash from operating activities | (342) | (555) | (171) | ||
CAPEX | |||||
Cash from investing activities | (14) | (14) | |||
Cash from financing activities | 685 | 679 | 250 | ||
FCF | (1,172) | 1,664 | 56,748 | ||
| Balance | |||||
Cash | 717 | 375 | 264 | ||
Long term investments | 23,634 | 26,167 | 90,714 | ||
Excess cash | 24,351 | 26,542 | 90,978 | ||
Stockholders' equity | 11,548 | 14,563 | 79,342 | ||
Invested Capital | 12,649 | 12,133 | 11,578 | ||
ROIC | 15.11% | 500.15% | |||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 169,129 | 168,395 | 168,239 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (1,313) | (821) | (752) | ||
EV/EBITDA | |||||
Interest | 21 | 21 | 13 | ||
Interest/NOPBT | |||||